Decoding cancer – Defining the optimal treatment option for each individual patient
Early detection of potentially fatal diseases and the selection of suitable therapies are crucial for successful treatment. BioNTech Diagnostics is working to provide innovative products and services to help medical professionals diagnose and characterize diseases with the final goal of extending the lives of patients and improving their quality of life. The Company currently focuses on the development of new diagnostic products and services in oncology.
We recently introduced MammerTyper®, a molecular in vitro diagnostic test for the quantitative detection of the mRNA expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. MammerTyper® has been shown in a variety of scientific publications to offer superior diagnostics insights compared to conventional immunohistochemical detection methods.
To make truly personalized medicine broadly available and to develop products and services for the next generation of personalized diagnostics and therapies.
To shape the future of medical testing by offering the tools to define the best therapeutic option for each individual patient with our extensive product and service offerings including biomarker discovery/validation and patient stratification and clinical monitoring by companion diagnostics (CDx).